Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
SpringWorks Therapeutics, Inc. SWTX
$28.13
+$0.29 (1.04%)
На 18:02, 12 мая 2023
+160.68%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
1593721466.00000000
-
week52high
40.72
-
week52low
13.60
-
Revenue
6147000
-
P/E TTM
-5268
-
Beta
0.58079400
-
EPS
-5.24000000
-
Last Dividend
0.00000000
-
Next Earnings Date
02 авг 2023 г. в 10:30
Описание компании
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. In addition, the company has clinical collaboration agreement with Janssen Biotech, Inc., Precision BioSciences, Inc., Seagen Inc., and AbbVie, Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 09 авг 2022 г. |
| Goldman Sachs | Buy | Buy | 13 июн 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 06 июн 2022 г. |
| Wedbush | Outperform | Outperform | 27 мая 2022 г. |
| Goldman Sachs | Buy | Buy | 24 мая 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 12 сент 2022 г. |
| Goldman Sachs | Buy | Buy | 21 окт 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 04 ноя 2022 г. |
| B of A Securities | Buy | 01 дек 2022 г. | |
| Goldman Sachs | Buy | Buy | 26 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Pichl Daniel | D | 35203 | 858 | 26 янв 2023 г. |
| Islam Saqib | D | 905104 | 4097 | 07 янв 2023 г. |
| Nofi Michael | D | 16855 | 409 | 07 янв 2023 г. |
| Edris Badreddin | D | 237223 | 1483 | 07 янв 2023 г. |
| Weinstein Herschel S | D | 35830 | 909 | 07 янв 2023 г. |
| Smith L. Mary | D | 212219 | 1068 | 07 янв 2023 г. |
| Perier Francis I Jr | D | 43463 | 1090 | 07 янв 2023 г. |
| Pichl Daniel | D | 36061 | 546 | 07 янв 2023 г. |
| Pichl Daniel | D | 36607 | 1719 | 06 янв 2023 г. |
| Weinstein Herschel S | D | 36739 | 1782 | 06 янв 2023 г. |
Новостная лента
SpringWorks Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
GlobeNewsWire
03 янв 2023 г. в 07:00
STAMFORD, Conn., Jan. 03, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that Saqib Islam, Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 7:30 a.m. PT.
Here's Why You Should Consider Investing in JAZZ Stock Now
Zacks Investment Research
17 окт 2022 г. в 12:03
JAZZ's new drugs like Xywav, Rylaze and Zepzelca, along with the recently-acquired drugs, are expected to generate 65% of product revenues in 2022.
SpringWorks (SWTX), GSK Expand Deal to Treat Multiple Myeloma
Zacks Investment Research
08 сент 2022 г. в 14:18
Per the partnership, SpringWorks Therapeutics (SWTX) will supply nirogacestat to GSK's (GSK) development program for its multiple myeloma drug, Blenrep.
SpringWorks Therapeutics to Present at the 2022 Wedbush PacGrow Healthcare Conference
GlobeNewsWire
02 авг 2022 г. в 07:00
STAMFORD, Conn., Aug. 02, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that management will participate in a fireside chat at the 2022 Wedbush PacGrow Healthcare Conference on Wednesday, August 10th at 10:55 a.m. ET.
SpringWorks Therapeutics Shares Jump On HC Wainwright Bullish Pitch
Benzinga
13 июн 2022 г. в 09:14
HC Wainwright points out that investors are enthusiastic about SpringWorks Therapeutics Inc (NASDAQ: SWTX) nirogacestat clinical profile for desmoid tumors after the R&D day held last week. As per a survey of U.S. oncologists treating patients with desmoid tumors, roughly 80%.